Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
New Board of Directors and management team at Suven Pharma also appointed
Minister was briefed on the nationwide dengue situation
Lupin has been exclusively marketing these brands in the Indian market since July 2021
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Subscribe To Our Newsletter & Stay Updated
